

Prior Authorization Request Form Fax Back To: (866) 940-7328

Phone: (800) 310-6826

## **Specialty Medication Prior Authorization Cover Sheet**

(This cover sheet should be submitted along with a Pharmacy Prior Authorization Medication Fax Request Form. Please refer to <a href="https://www.uhcprovider.com">www.uhcprovider.com</a> for medication fax request forms.)

Patient's Name:						
Insurance ID: Date of Birth: Height: Weight:						
Address: Apartment #:						
City: State: Zip Code:						
Phone Number: Alternate Phone: Sex: Male Fema	le					
Provider Information						
Provider's Name: Provider ID Number:						
Address: City: State: Zip Code:						
Suite Number: Building Number:						
Phone Number: Fax number:						
Provider's Specialty:						
Medication Information						
Medication: Quantity: ICD10 Code:						
Directions: Diagnosis: Refills:						
Physician Signature**: Initial here if DAW:						
Physician Signature**: By signing above, the physician is providing the specialty pharmacy with a prescription that can be used to facilitate the dispensing and/or coordination of delivery for the requested medication.						
Medication Instructions						
Has the patient been instructed on how to <b>Self-Administer</b> ? ☐ Yes ☐ No						
Is this medication a <b>New Start</b> ?						
If continuation please provide the following: Initiation Date: / / Date of Last Dose: / /						
Is there documentation of positive clinical response to current therapy?						
**Please attach any pertinent clinical information that would pertain to support stated diagnosis.  Additional clinical information may be needed depending on your patients plan, including medication(s) previously tried and failed.						
Delivery Instructions						
Delivery instructions	Note: Delivery coordination requires a "Physician Signature" above <u>and complete</u> "Provider Information" <u>and</u> "Patient Information"  Note: All necessary ancillary supplies are provided free of charge to the patient at the time of delivery					
Note: Delivery coordination requires a "Physician Signature" above and complete "Provider Information" and "Patient Information"						
Note: Delivery coordination requires a "Physician Signature" above and complete "Provider Information" and "Patient Information"						



## Tarceva - Washington

## PRIOR AUTHORIZATION REQUEST FORM

Please complete this entire form and fax it to: 866-940-7328. If you have questions, please call 800-310-6826.

This form contains multiple pages. Please complete all pages to avoid a delay in our decision.

Allow at least 24 hours for review.

Section A - Member Inform	nation							
First Name:	Name: Last Name:				Member ID:			
Address:								
City:		State:			ZIP Code:			
Phone:		DOB:			Allergies:			
Primary Insurance Information:		•		<b>1</b>				
Is the requested medication	n □ New or □ C	Continuation	on of Therapy? If c	ontinuation, list	t start date:			
Is this patient currently hos	spitalized?	Yes □ No	If recently discha	rged, list discha	arge date:			
Section B - Provider Inform	nation							
First Name:			Last Name:			M.D./D.O.		
Address:			City:		State:	ZIP code:		
Phone:	Fax:		NPI #:		Specialty:			
Office Contact Name / Fax a	ttention to:							
Section C - Medical Inform Medication:	ation				Strength:			
Directions for use:					Quantity:			
Diagnosis (Please be specif	fic & provide as	much info	rmation as possible)	):	ICD-10 CO	DE:		
la thia mamban manant?	- Vaa - Na	lf	bat ia thia man	hawla dua data?				
Is this member pregnant?   Yes No If yes, what is this member's due date?								
Section D - Previous Medic	cation Trials							
Section D – Previous Medications		ngth	Directions	Dates of The	. 1. 2	on for failure /		
		ngth	Directions	Dates of The	. 1. 2	on for failure / continuation		
		ngth	Directions	Dates of The	. 1. 2			
		ngth	Directions	Dates of The	. 1. 2			
		ngth	Directions	Dates of The	. 1. 2			
Medications  Section E – Additional infor	Stre	planation	of why preferred m	nedications wou	dis	continuation  ne patient's needs:		
Medications  Section E – Additional infor	Stre	planation		nedications wou	dis	continuation  ne patient's needs:		
Medications  Section E – Additional infor	Stre	planation	of why preferred m	nedications wou	dis	continuation  ne patient's needs:		
Medications  Section E – Additional infor	Stre	planation	of why preferred m	nedications wou	dis	continuation  ne patient's needs:		
Medications  Section E – Additional infor	Stre	planation	of why preferred m	nedications wou	dis	continuation  ne patient's needs:		
Medications  Section E – Additional infor	Stre	planation	of why preferred m	nedications wou	dis	continuation  ne patient's needs:		
Medications  Section E – Additional infor	Stre	planation	of why preferred m	nedications wou	dis	continuation  ne patient's needs:		
Medications  Section E – Additional infor	Stre	planation	of why preferred m	nedications wou	dis	continuation  ne patient's needs:		
Medications  Section E – Additional infor	Stre	planation	of why preferred m	nedications wou	dis	continuation  ne patient's needs:		
Medications  Section E – Additional infor	Stre	planation	of why preferred m	nedications wou	dis	continuation  ne patient's needs:		



Physician Signature:

## Tarceva - Washington

PRIOR AUTHORIZATION REQUEST FORM

Date:

Member First name:		Member Last name:	Member DOB:				
Clinical and Drug Specific Information							
ALL REQUESTS							
□ Yes □ No	Does the patient have any of the following diagnoses? (If yes, check which applies)  □ Pancreatic Cancer □ Non-Small Cell Lung Cancer (NSCLC)						
□ Yes □ No Is the medication being requested for a use supported by the National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium?  If yes, list supported use:							
PANCREATIC CANCER							
□ Yes □ No	Is the patient's disease locally advanced, unresectable, or metastatic?						
□ Yes □ No	es   No Will Tarceva be used in combination with Gemzar (gemcitabine)?						
NON-SMALL CELL LUNG CANCER (NSCLC)							
□ Yes □ No	Is the patient's disease r	netastatic or recurrent?					
□ Yes □ No	Does the patient have any of the following: (If yes, check which applies)  □ Tumors are positive for epidermal growth factor receptor (EGFR) exon 19 deletions  □ Tumors are positive for exon 21 (L858R) substitution mutations  □ Tumors are positive for a known sensitizing EGFR mutation (e.g. in-frame exon 20 insertions, exon 18 G719 mutation, exon 21 L861Q mutation)						
KIDNEY CANCER							
□ Yes □ No	Does the patient have one of the following?  □ Diagnosis of stage IV kidney cancer □ Disease is relapsed						
□ Yes □ No	Is the patient's disease o	of non-clear cell histology?					
METASTATIC BRAIN CANCER FROM NSCLC							
□ Yes □ No	Does the patient have any of the following: (If yes, check which applies)  □ Tumors are positive for epidermal growth factor receptor (EGFR) exon 19 deletions  □ Tumors are positive for exon 21 (L858R) substitution mutations						
CONTINUATION OF THERAPY							
□ Yes □ No		ressive disease while on Tarceva thera	• •				
□ Yes □ No	Is there documentation of positive clinical response to therapy?  If yes, list positive response:						

**Confidentiality Notice:** This transmission contains confidential information belonging to the sender and UnitedHealthcare. This information is intended only for the use of UnitedHealthcare. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action involving the contents of this document is prohibited. If you have received this telecopy in error, please notify the sender immediately.